Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-0822

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Background Tartrate–resistant acid phosphatase (TRAP/ ACP5) belongs to the binuclear metallophosphatase family and is present in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2019
Review
2019
Belongs to the metabolic disease with the highest incidence rate. The middle-aged and elderly people are the main disease group… Expand
2012
2012
Odanacatib (ODN, MK-0822) is an investigational drug under development for the treatment of osteoporosis. A quantitative LC/MS-MS… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Review
2011
Review
2011
Bone homeostasis is maintained by delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts… Expand
2009
2009
An enantioselective synthesis of the Cathepsin K inhibitor odanacatib (MK-0822) 1 is described. The key step involves the novel… Expand
Review
2009
Review
2009
  • E. Lewiecki
  • IDrugs : the investigational drugs journal
  • 2009
  • Corpus ID: 44224955
Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under license… Expand
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… Expand